semaglutide in thigh vs stomach Ozempic Injection Sites Why they recommend to avoid

The Phase 3 ATTAIN-1 trial had good results that led to this approval, but not all positive: 12.4% average weight loss (27.3 lbs) at highest dose Lower than the 15-20% weight loss seen with injectables Wegovy and Zepbound Nearly 1/4 of participants on the highest dose reported vomiting Vomiting rates are much higher than injectable GLP-1s However, there is likely a niche for Foundayo (along with the pill version of Wegovy) due to convenience: No refrigeration requirements or injection site reactions Eliminates barriers for patients avoiding injectables due to stigma, needle aversion, or storage constraints It's possible we could see this as a "maintenance" therapy after an initial injectable course

Oral semaglutide can cause nausea, vomiting, and appetite suppression in the first weeks of treatment

As interest in GLP-1 grows, our role remains clear: deliver high-quality clinical care and support the patient, not just the medication

Diabetes can lead to yet more major complications: heart disease, nerve damage, stroke, and kidney disease